Adherence to anti-psychotic medications and Health Behavior theories

Journal of Mental Health

Volumn 11, Issue 3, 2002, Pages 243-254

  Corrigan, Patrick W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

COGNITION; DISEASE MODEL; DOCTOR PATIENT RELATION; FAMILY; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HUMAN; PATIENT COMPLIANCE; REVIEW; SOCIAL DISABILITY; SOCIAL SUPPORT; THEORETICAL MODEL;

EID: 0036314270     PISSN: 09638237     EISSN: None     Source Type: Journal    
DOI: 10.1080/09638230020023633     Document Type: Review

References (82)

1. Awareness of illness in schizophrenia
2. Assessment of insight in psychosis
3. Awareness of illness in schizophrenia and schizoaffective and mood disorders
4. Practice guidelines for the treatment of patients with schizophrenia
5. Olanzapine versus placebo and halperidol: Acute phase results of the North American double-blind olanzapine trial
6. Treating substance abuse among patients with schizophrenia
7. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
8. The clinical characteristics of schizophrenic patients consenting or not consenting to a placebo controlled trial of antipsychotic medication
9. Operation outreach: Intensive case management for severely psychiatrically disabled adults
10. The omnipotence of voices: A cognitive approach to auditory hallucinations
11. A cognitive approach to measuring and modifying delusions
12. Assessing compliance to anti-hypertensive medications using computer-based pharmacy records
13. Social adjustment of patients living at home
14. Social work practice with homeless mentally ill people: Engaging the client
15. Some considerations for research on consumer empowerment and psychosocial interventions
16. Aggressive versus problem-focused case management for the severely mentally ill
17. From noncompliance to collaboration in the treatment of schizophrenia
18. Motivational interviews as goal assessment for persons with psychiatric disability
19. Psychiatric Rehabilitation
20. Interpersonal problem solving and information processing in schizophrenia
21. Learning medication self-management skills in schizophrenia: Relationships with cognitive deficits and psychiatric symptoms
22. Models of case management and their impact on social outcomes of severe mental illness
23. Compliance with medication regimens for psychiatric and medical disorders
24. Awareness of illness in schizophrenia and outpatient treatment adherence
25. Psychological reactance and its relationship to normal personality variables
26. Cognitive therapy and recovery from acute psychosis: A controlled trial: I. Impact on psychotic symptoms
27. The neuropsychology of schizophrenia: Relations with clinical and neurobiological dimensions
28. Social action theory for public health psychology
29. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
30. Misconception about the Fishbein model: Reflections on a study by Songer-Nocks
31. Reactance theory and patient noncompliance
32. Cognitive behavioral therapy for drug-resistant psychosis
33. Lack of insight in psychotic and affective disorders: A review of empirical studies
34. What are the functional consequences of neurocognitive deficits in schizophrenia?
35. Use of prescription-refill records to assess patient compliance
36. Relapse in schizophrenia
37. Compliance with anti-psychotic medication: From theory to practice
38. Collaboration with drug treatment by schizophrenic patients with and without psychoeducational training: Results of a 1-year follow-up
39. The relevance of clinical pharmacokinetics and therapeutic drug monitoring: Anticonvulsant mood stabilizers and antipsychotics
40. The relationship between medication noncompliance and cognitive function in patients with schizophrenia
41. Compliance in psychosis
42. Clozapine for the treatment resistant schizophrenic: A double-blind comparison with chlorpromazine
43. Clinical case management: Definition, principles, components
44. Utilizing the health belief model in examining medication compliance
45. Insight and compliance
46. Compliance therapy in psychotic patients: Randomised controlled trial
47. Insight and adherence to medication in chronic schizophrenics
48. Risperidone in the treatment of schizophrenia
49. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
50. Motivational interviewing: Research, practice, and puzzles
51. Models of community care: A review of research on case management
52. Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder
53. Perspectives on intrapersonal theories in health education and health behavior
54. The meaning and management of neuroleptic medication: A study of patients with a diagnosis of schizophrenia
55. Patients' compliance with health regimens
56. The health belief model: Explaining health behavior through expectancies
57. Effectiveness of interventions to improve patient compliance: A meta-analysis
58. Psychiatric patients' attitudes about medication and factors affecting noncompliance
59. Neuropsychological function in schizophrenia: Selective impairment in memory and learning
60. Assertive community treatment and case management for schizophrenia
61. Non-compliance with anti-psychotic depot medication: Users' views on advantages and disadvantages
62. Advance directives for mental health treatment
63. Alternative to mental hospital treatment: I. Conceptual model, treatment program and clinical evaluation
64. The assessment of refill compliance using pharmacy records: Methods, validity, and applications
65. Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients
66. A trial of two cognitive-behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients: I. Outcome
67. Some reasons why patients suffering from chronic schizophrenia fail to continue in psychological treatment
68. Cost of relapse in schizophrenia
69. Medication noncompliance in schizophrenia: Effects on mental health service policy
70. Motivation-based assessment and treatment of substance abuse in patients with schizophrenia